• How Dual-Action Inhibitors Control p38α Dephosphorylation

  2026-08-15

  The reference study shows that selected kinase inhibitors can do more than occupy the p38α active site: they can also expose the activation-loop phosphothreonine to the phosphatase WIP1 and accelerate dephosphorylation. This structure-guided mechanism links kinase inhibition with phosphatase-mediated pathway shutdown and suggests a route toward more selective control of p38 MAPK signaling.

• ABT-263 (Navitoclax) Apoptosis Workflow

  2026-08-15

  ABT-263 (Navitoclax) turns Bcl-2 family dependence into a measurable experimental variable for apoptosis, mitochondrial priming, and cancer biology studies. This workflow combines dose-response design with phase-aware controls inspired by primary leukemia research, helping distinguish caspase-dependent apoptosis from alternative cell-death outcomes.

• Deep Learning Detects Cardiotoxicity in iPSC-CMs

  2026-08-14

  Grafton et al. developed a high-content screening strategy that combines induced pluripotent stem cell-derived cardiomyocytes with deep learning to identify cellular patterns associated with drug-induced cardiotoxicity. The approach converts complex image-based phenotypes into a single screening score, offering an early, scalable method for prioritizing compounds that may require mechanistic or safety follow-up.

• Podophyllotoxin: From Mitotic Arrest to Assay Logic

  2026-08-14

  Podophyllotoxin is more than a microtubule inhibitor: it is a powerful experimental anchor for separating mitotic arrest, apoptosis, autophagy, and multidrug-resistance phenotypes. This guide translates parent-compound biology and derivative 5p evidence into better assay decisions.

• Cell-Cycle Data as a Translational Decision Tool

  2026-08-13

  DNA-content profiling is more than a descriptive endpoint: it can connect pathway perturbation with proliferative state, apoptotic loss, and translational confidence. This article explains how PI-based flow cytometry, exemplified by the Cell Cycle Assay Kit (Catalog No. K2263), can sharpen mechanistic studies such as GANT61 treatment in ALK-positive anaplastic large cell lymphoma.

• MARCH5 and Mitochondria-Derived Pre-Peroxisomes

  2026-08-13

  Zheng and colleagues identify mitochondrial MARCH5 as a key regulator of PEX3-containing vesicles that initiate de novo peroxisome biogenesis. Their findings distinguish pre-peroxisome production from other mitochondria-derived vesicle pathways and provide a mechanistic framework for studying organelle homeostasis in human cells.

• Tunable Human Intestinal Organoids: Study Insights

  2026-08-12

  The reference study introduces a human small intestinal organoid system that maintains high proliferation while supporting broader epithelial differentiation under one culture condition. Its central innovation is the use of coordinated pathway modulation to strengthen stemness and then tune lineage allocation, offering a more scalable platform for intestinal biology and screening.

• Naringin, VEGFC, and Macrophages in NASH Fibrosis

  2026-08-12

  The reference study identifies a hepatocyte-derived VEGFC–VEGFR-3 signaling axis that promotes macrophage recruitment and sustains inflammatory phenotypes during high-fat diet-induced hepatic fibrosis. By combining pharmacological inhibition, hepatocyte-specific Vegfc deletion, clinical samples, public transcriptomic datasets, and cell-based assays, the work provides a mechanistic explanation for naringin’s protective effects and supports VEGFR-3 inhibition as a preclinical strategy for studying metabolic liver disease.

• M. tuberculosis WecA: Purification and Kinetics

  2026-08-11

  The reference study establishes a controlled Escherichia coli expression, affinity purification, and activity assay workflow for Mycobacterium tuberculosis WecA, an 11-transmembrane-domain enzyme linked to mycobacterial cell-wall synthesis. By measuring UMP formation and showing competitive inhibition by tunicamycin, the work provides a practical biochemical foundation for WecA mechanism studies and inhibitor discovery.

• Polymyxin B: A Perturbation Tool for Immune Assays

  2026-08-10

  Polymyxin B sulfate is more than a bactericidal reagent: it can function as a controlled perturbation in Gram-negative infection, dendritic-cell, and microbiome-linked studies. This guide shows how to separate membrane killing, endotoxin effects, and immune readouts for more interpretable experiments.

• Weight Loss Restores Gut Stretch Satiety in Obesity

  2026-08-09

  The reference study shows that intestinal stretch acutely suppresses food intake and improves oral glucose tolerance, even when classical GLP-1 signaling and vagal intestinal mechanosensation are disrupted. Obesity weakens this response, whereas dietary weight loss and vertical sleeve gastrectomy restore behavioral and brainstem responses, identifying mechanical gut feedback as a distinct metabolic pathway.

• Liproxstatin-1 HCl: Mechanism to Assay Design

  2026-08-08

  Liproxstatin-1 HCl is more than a potent ferroptosis inhibitor: it is a mechanistic rescue probe for connecting lipid peroxidation, GPX4 activity, and mitochondrial calcium signaling. This guide shows how to use it to interpret ferroptosis assays and bridge cellular findings to injury models.

• Dabigatran Etexilate: Oral Direct Thrombin Inhibition

  2026-08-07

  The reference review presents dabigatran etexilate as the first oral direct thrombin inhibitor marketed in the United States, emphasizing its rapid, predictable anticoagulant activity and independence from cytochrome P-450 metabolism. Its clinical value lies in addressing practical limitations of vitamin K antagonists and injectable anticoagulants, while renal function, bleeding, and gastrointestinal tolerability remain important considerations.

• Resazurin Cell Viability Assays: Bridging Mechanism to Trans

  2026-08-07

  Explore the mechanistic underpinnings and strategic implications of the Resazurin Cell Viability Assay Kit for cutting-edge translational research. This article provides actionable guidance, evidence integration, and benchmarking to empower researchers transitioning from basic discovery to impactful preclinical and clinical workflows.

• Sodium Dicloxacillin Monohydrate: Intracellular PK/PD and MS

  2026-08-06

  Explore the nuanced pharmacodynamics of sodium dicloxacillin monohydrate in MSSA research. This article uniquely dissects intracellular versus extracellular efficacy, protocol design, and PK/PD optimization, offering advanced insights for antibiotic mechanism of action studies.

454 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page